相关实验视频
Updated: Jul 19, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
对于控制不良的2型糖尿病患者,启动胰岛素治疗
Hsin-An Chen1, Chia-Hung Lin2,3, Feng-Hsuan Liu2,3
1Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC.
Journal of the Chinese Medical Association : JCMA
|March 28, 2025
概括
胰岛素治疗在3个月内有效降低2型糖尿病 (T2DM) 患者的血糖. 那些初始葡萄糖水平较高的人在血糖控制方面表现出最大的改善.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药物治疗 药物治疗
背景情况:
- 2型糖尿病 (T2DM) 的管理往往需要胰岛素治疗,对于控制不良的病例.
- 评估血糖反应和患者资料对于优化T2DM治疗至关重要.
研究的目的:
- 检查T2DM患者开始胰岛素治疗的情况.
- 分析血糖反应,并根据结果比较患者的个人资料.
主要方法:
- 开始胰岛素治疗的T2DM患者的回顾性分析.
- 处理前收集的数据和开始后的3个月和6个月.
- 主要结局:血红蛋白A1c (HbA1c) 在6个月;次要结局:HbA1c在3个月,禁食血糖 (FBG) 在3个月和6个月.
主要成果:
- 胰岛素在6个月内显著降低了HbA1c (9.8%至7.7%) 和FBG (221.4至144.2 mg/dL).
- 在3个月内观察到的改善:HbA1c (至8.2%),FBG (至147.2 mg/dL).
- 较高的基线葡萄糖预测了更大的HbA1c降低;更好的响应者更早地降低了FBG和HbA1c.
结论:
- 胰岛素治疗迅速显著改善T2DM的血糖控制.
- 患有较高基线高血糖症的患者表现出对胰岛素治疗的反应增强.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

